简介：
Overview
This study demonstrates a protocol for genome editing in hematopoietic cells using preassembled Cas9/guide RNA ribonucleoprotein complexes. The focus is on deleting a RUNX1 intronic silencer and assessing the transcriptional responses in OCI-AML3 leukemic cells.
Key Study Components
Area of Science
- Genome Editing
- Hematopoietic Cell Biology
- Leukemia Research
Background
- Cis-regulatory elements are crucial for gene expression.
- Traditional methods for studying these elements are often complex and time-consuming.
- CRISPR technology offers a streamlined approach to investigate gene regulation.
- Electroporation enhances the delivery of CRISPR components into difficult-to-transfect cells.
Purpose of Study
- To utilize CRISPR for examining the role of a RUNX1 intronic silencer.
- To improve editing efficiency and cell viability in hematopoietic cells.
- To provide a simple protocol for fast assessments of gene regulatory functions.
Methods Used
- Designing CRISPR RNAs flanking the target cis-regulatory element.
- Electroporating preassembled Cas9/gRNA complexes into OCI-AML3 cells.
- Using fragment analysis for screening mutant clones.
- Performing real-time PCR for transcript quantification.
Main Results
- The RUNX1 intronic silencer was successfully deleted.
- Capillary gel electrophoresis confirmed the deletion.
- Mutant levels greater than 95% were achieved in selected clones.
- Transcriptional responses were assessed post-deletion.
Conclusions
- This protocol provides an efficient method for genome editing in hematopoietic cells.
- It allows for rapid evaluation of gene regulatory elements in their endogenous context.
- The approach minimizes off-target effects and enhances cell viability.
What is the main advantage of using CRISPR in this study?
CRISPR allows for precise editing of the RUNX1 intronic silencer with improved efficiency and reduced off-target effects.
How does electroporation improve the delivery of CRISPR components?
Electroporation enhances the uptake of the Cas9/gRNA complexes into hematopoietic cells, which are typically hard to transfect.
What are the expected sizes of the PCR products?
The wild-type PCR product is approximately 500 base pairs, while the mutant product is about 230 base pairs.
How is the success of the gene editing confirmed?
Success is confirmed through capillary gel electrophoresis and analysis of mutant levels.
What is the significance of the RUNX1 gene in leukemia?
RUNX1 is a critical regulator of hematopoiesis, and its dysregulation is often implicated in leukemia.
Can this protocol be applied to other genes?
Yes, the protocol can be adapted for editing other cis-regulatory elements in different genes.
繁體中文
